Novartis
Novartis Invests $1 Billion in PTC Therapeutics’ Huntington’s Disease Program
Novartis, PTC Therapeutics, Huntington’s disease, Phase 2 drug, global license agreement, collaboration, upfront payment, milestone payments.
Novartis Announces 139 Layoffs in New Jersey Amid Ongoing Restructuring Efforts
Novartis, layoffs, New Jersey, restructuring, pharmaceutical industry
Novartis Announces 139 Job Cuts in New Jersey Amid Commercial Refocus
Novartis, job cuts, New Jersey, commercial refocus, restructuring
Biopharma Companies Continue Layoffs: Novartis, Recursion, and Kronos Reduce Staff Amid Industry Restructuring
Biopharma layoffs, Novartis restructuring, Recursion, Kronos, pharmaceutical industry, workforce reduction, cost-cutting measures
Novartis Enhances Mid-Term Growth Projections Following Strategic Transformation
Novartis, mid-term guidance, growth projections, pharmaceutical industry, innovative medicines, pipeline development
Novartis CEO Reveals Strategic Pipeline Reduction by 40% Based on Data-Driven Insights
Novartis, clinical pipeline, data-driven decisions, pharmaceutical industry, strategic reduction
Novartis and Ratio Therapeutics Ink $745M Radiopharmaceutical Deal
Novartis, Ratio Therapeutics, radiopharmaceutical pact, $745M deal, cancer treatment
Novartis and Schrödinger Forge $150M Drug Discovery Partnership with Billions in Potential Milestones
Novartis, Schrödinger, drug discovery pact, $150M upfront payment, multiyear collaboration, multi-target agreement.
Novartis Joins Eurovision 2025 as Official Partner
Eurovision 2025, Novartis, Official Partner, Basel, Switzerland
Novartis Secures First-Line Approval for Scemblix in Newly Diagnosed Chronic Myeloid Leukemia Patients
Scemblix, Novartis, first-line approval, chronic myeloid leukemia, CML, newly diagnosed, FDA approval